Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, on the use of angiogenesis inhibitors for the treatment of metastatic gastric cancer.
Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, on the use of angiogenesis inhibitors for the treatment of metastatic gastric cancer.
Read more aboutthe phase II study
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More